Resumen

TORRES, Gina et al. Biphenotypic  acute leukemia: case report. Cuad. - Hosp. Clín. [online]. 2015, vol.56, n.2, pp.45-48. ISSN 1562-6776.

Biphenotypic acute leukemia (BAL) is an uncommon disease comprising approximately from 2 to 5% of all leukemia cases. BAL is characterized by the associated expression of two or more markers of different cell lines in a single blasts population. In this regard, 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues included EGIL score system for diagnosing this type of leukemia. The biphenotypic leukemia that expresses B and T phenotypes is extremely unusual and it has poor prognosis. Due to low incidence of BAL, it is not possible to conduct randomized trials and consequently little is known about the clinical management of this kind of patients. Currently, there is no a standard treatment for these cases. However, the use of Hyper-CVAD regimen (hyperfractionated of cyclophosphamide, vincristine, adriamycin, and dexamethasone; and high dose of methotrexate and cytarabine) has achieved a 78% of complete remission with an average survival of 27 months; and the incorporation of tyrosine kinase inhibitors (imatinib, nilotinib or dasatinib) has improved the remission rate during induction. We report the case of a patient whose clones gave positive for B and T lymphoid markers and according to EGIL score system, it was obtained 6.5 for B lineage and 4.5 for Tlineage

        · resumen en Español     · texto en Español     · Español ( pdf )